Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2012

View Archived Issues

New ESC guidelines recommend use of ticagrelor

Symphogen licenses Sym-004 to Merck KGaA

FDA continues review of crofelemer NDA beyond PDUFA date

ValiRx reports data on VAL-201 for breast cancer

Novel HDAC inhibitors prepared at Dana Farber Cancer Institute

CSIR patents novel agents for cancer

Glenmark Pharmaceuticals prepares new MPGES-1 inhibitors

Novel DGAT1 inhibitors synthesized by Merck & Co.

Scientists at BioRelix present new flavin derivatives

Phase II zabofloxacin results presented at ICAAC

Generon begins clinical studies of IL-22 product

FG-3019 safe and well tolerated in phase II study in IPF

Aileron Therapeutics reports on new therapeutic drug program

NeurOp receives NIH funding for ischemia research

PM-01183 receives positive opinion for orphan drug status in E.U.

Sanofi develops new 11-beta-HSD1 inhibitors for the treatment of diabetes

InSite Vision completes enrollment of DOUBle study

Janssen makes submissions to the FDA for two different Xarelto sNDAs

SFJ and Pfizer sign agreement to codevelop treatment for advanced NSCLC

Atu-111 shows efficacy in preclinical model of acute lung injury

Phase I/II trial of Astex's HSP 90 inhibitor begins

Cedars-Sinai Heart Institute receives funding to further study cardiac stem cells

AstraZeneca discontinues development of candidate in obesity collaboration with Palatin

Actinium to begin screening patients for second cohort of phase I/II trial in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...